BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Ventria Bioscience Acquires Meristem Therapeutics' Recombinant Lactoferrin Intellectual Property


12/3/2012 10:27:31 AM

FORT COLLINS, Colo.--(BUSINESS WIRE)--Ventria Bioscience announces the completion of an agreement under which Ventria Bioscience will wholly acquire portions of the intellectual property portfolio relating to Recombinant Lactoferrin developed by the French biotechnology company, Meristem Therapeutics. The agreement transfers to Ventria Bioscience exclusive royalty-free ownership rights for the specific patents in the United States, France, and Canada, including those related to recombinant human lactoferrin, in exchange for a one-time payment. “The patents acquired today cover important components of our product pipeline,” said Scott Deeter, president and CEO of Ventria Bioscience. “The decision to purchase this intellectual property is significant because it removes the encumbrance of ongoing royalty and milestone payments, thereby enhancing the future economics of our products that use recombinant human lactoferrin.”

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES